Tranexamic Acid versus Naproxen for Menorrhagia
Tranexamic acid is superior to naproxen (and other NSAIDs) for treating heavy menstrual bleeding, reducing menstrual blood loss by 26-60% compared to NSAIDs' more modest 34-47% reduction. 1, 2, 3
Efficacy Comparison
Tranexamic acid demonstrates significantly greater efficacy:
- Reduces menstrual blood loss by 26-60% from baseline 2
- More effective than NSAIDs including naproxen and mefenamic acid in head-to-head trials 1, 3
- One direct comparison showed mefenamic acid resulted in 64.26 mL less blood loss than tranexamic acid (favoring tranexamic acid) 4
Naproxen and other NSAIDs show more modest results:
- Reduce menstrual blood loss by 34-47% 5, 6
- Naproxen specifically reduced bleeding by 46% in controlled trials 5
- NSAIDs are more effective than placebo but consistently less effective than tranexamic acid 1, 3
Dosing Regimens
Tranexamic acid:
- 3.9-4 g/day divided into doses for 4-5 days starting from the first day of menstruation 2, 7
- Taken only during menstruation, not continuously 8
Naproxen:
- Standard dosing for menorrhagia: 375-750 mg twice daily during menstruation 9
- Can be used for 5-7 days during bleeding episodes 10
Safety Profile
Tranexamic acid safety:
- No evidence of increased thrombotic events in women without cardiovascular disease [2, @30@]
- Contraindicated in active thromboembolic disease or history of thrombosis 10
- FDA warning includes intrinsic risk for thrombosis as contraindication 10
- Gastrointestinal side effects (nausea, vomiting, diarrhea) occur in approximately 12% of patients 6
Naproxen safety:
- Generally well-tolerated with fewer GI side effects than aspirin or indomethacin 9
- Standard NSAID precautions apply (GI bleeding, renal effects, cardiovascular risk with prolonged use)
Critical Clinical Context
Important caveat for cardiovascular disease: In women with spontaneous coronary artery dissection (SCAD) or significant cardiovascular disease, both NSAIDs and tranexamic acid should generally be avoided due to associations with MI and thrombosis 11. In this specific population, hormonal options (levonorgestrel IUD) or surgical interventions are preferred.
Quality of Life Impact
Tranexamic acid significantly improves quality of life metrics:
- 81% of women reported satisfaction with treatment 6
- 94% judged menstrual blood loss as "decreased" or "strongly decreased" 6
- Reduces limitations on physical, social, and leisure activities 8
Duration of Treatment Effect
- Tranexamic acid: Effects last only during treatment; no carryover benefit 2
- NSAIDs: Similarly, effects are limited to treatment period 1
- Neither medication affects duration of menses significantly 6, 4
When to Choose Each Agent
Choose tranexamic acid when:
- Maximum efficacy is needed for heavy menstrual bleeding
- Patient has no history of thromboembolism
- Hormonal contraception is contraindicated or unwanted
- Patient prefers non-hormonal therapy
Choose naproxen when:
- Dysmenorrhea is a prominent symptom (NSAIDs have analgesic benefit)
- Bleeding is moderate rather than severe
- Patient has contraindications to tranexamic acid
- Cost is a significant barrier (NSAIDs are generally less expensive)
The evidence consistently demonstrates tranexamic acid as the more effective non-hormonal medical therapy for heavy menstrual bleeding, with a well-established safety profile in appropriately selected patients.